Hostname: page-component-7b7567c8c-9cwtv Total loading time: 0 Render date: 2026-11-19T15:10:45.037Z Has data issue: false hasContentIssue false

Impact of a monthly antimicrobial stewardship quality assurance tool for elevated vancomycin levels

Published online by Cambridge University Press:  15 March 2023

Olivia C. Knack
Affiliation:
Clinical Pharmacy Enterprise, Baptist Health South Florida, Miami, Florida
Alice M. Landayan
Affiliation:
Department of Pharmacy, Baptist Health South Miami Hospital, Miami, Florida
Kelsey N. Williams
Affiliation:
Department of Pharmacy, Baptist Hospital of Miami, Miami, Florida
Lee M. Amaya
Affiliation:
Department of Pharmacy, Baptist Health Miami Cancer Institute, Miami, Florida
Timothy P. Gauthier*
Affiliation:
Clinical Pharmacy Enterprise, Baptist Health South Florida, Miami, Florida
*
Author for correspondence: Timothy P. Gauthier, Department of Pharmacy, Baptist Health Miami Cancer Institute, 8900 N Kendall Drive, Miami, FL 33176. E-mail: timothyga@baptisthealth.net

Abstract

Objective:

We sought to determine the value of an audit-and-feedback monitoring method in facilitating meaningful practice changes to improve vancomycin dosing and monitoring.

Design:

Retrospective, multicenter, before-and-after implementation observational quality assurance initiative.

Setting:

The study was conducted in 7 not-for-profit, acute-care hospitals within a health system in southern Florida.

Methods:

The preimplementation period (September 1, 2019, through August 31, 2020) was compared to the postimplementation period (September 1, 2020, through May 31, 2022). All vancomycin serum-level results were screened for inclusion. The primary end point was the rate of fallout, defined as vancomycin serum level ≥25 µg/mL with acute kidney injury (AKI) and off-protocol dosing and monitoring. Secondary end points included the rate of fallout with respect to AKI severity, rate of vancomycin serum levels ≥25 µg/mL, and average number of serum-level evaluations per unique vancomycin patient.

Results:

In total, 27,611 vancomycin levels were analyzed from 13,910 unique patients. There were 2,209 vancomycin serum levels ≥25 µg/mL (8%) among 1,652 unique patients (11.9%). AKI was identified in 379 unique patients (23%) with a vancomycin levels ≥25 µg/mL. In total, 60 fallouts (35.2%) occurred in the 12-month preimplementation period (∼5 per month) and 41 fallouts (19.6%) occurred in the 21-month postimplementation period (∼2 per month; P = .0006). Failure was the most common AKI severity in both periods (risk: 35% vs 24.3%, P = .25; injury: 28.3% vs 19.5%, P = .30; failure: 36.7% vs 56%, P = .053). Overall, the number of evaluations of vancomycin serum levels per unique patient remained consistent throughout both periods (2 vs 2; P = .53).

Conclusions:

Implementation of a monthly quality assurance tool for elevated outlier vancomycin levels can improve dosing and monitoring practices resulting in enhanced patient safety.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Definition for Fallout Reason With Example

Figure 1

Fig. 1.Sample vancomycin monitor.

Figure 2

Fig. 2.Vancomycin fall-outs per 3-month interval by site and combined.

Figure 3

Fig. 3.Determined reason for fallout by implementation phase.